companydata.dkNovo Nordisk Invest 4 A/S: Financial statements 2016
CVR: 31853923
Novo Nordisk Invest 4 A/S (CVR 31853923) has filed annual accounts for 2016. In 2016, the company reported a net result of DKK -407,000 compared with DKK 803,000 the year before. Equity amounted to DKK 9,923,000. The solvency ratio was 11.6%.
- Profit/Loss
- -407,000 kr.
- Equity
- 9,923,000 kr.
- Total Assets
- 85,549,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | - | -407 t. | 9.9 mio. | - |
| 2015 | 219.3 mio. | - | 803 t. | 10.3 mio. | - |
| 2013 | 181.8 mio. | - | -214 t. | 5.7 mio. | - |
How creditworthy is Novo Nordisk Invest 4 A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2016
Novo Nordisk Invest 4 A/S has published its annual report for 2015. Revenue came to DKK 219,295,000, and the net result was DKK 803,000.
About Novo Nordisk Invest 4 A/S
Novo Nordisk Invest 4 A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2008. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named STENO DIABETES CENTER A/S. The management consists of Anders Rytter Mikkelsen. The company is owned by NOVO NORDISK A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -64,000 and a net result of DKK -23,000 compared with DKK 7,000 the year before. Equity amounted to DKK 1,772,000.